The invention relates to the use of beta-blocking compounds, in particular the antagonist of β3 adrenoceptor (β3-ARs), for the treatment of immune-tolerance associated with pathological states, such as cancer.
The invention is represented by a mixture of molecules, called A_ATROFI, capable of regulating the balance between protein synthesis and its degradation in skeletal muscle cells.
The present invention targets a class of compounds able to activate the enzyme SIRT1 in humans by regulating numerous metabolic functions. The appropriately designed compounds could be used in pharmaceutical formulations, preferably in the treatment or prevention of cardiometabolic diseases
The present invention concerns the development of new pharmacologically active compounds for the treatment of osteoporosis and in general bone diseases characterized by progressive loss of bone mass, such as rheumatoid arthritis, hyperparathyroidism, and bone cancer metastases.
The invention relates to a sensorized high throughput bioreactor, that can be placed in series and/or parallel with similar systems, to subject vascular conduits of different sizes to chemical-physical, mechanical and electromagnetic stimuli, simulating physiological and pathological conditions present within an [...]
The invention consists of a method to activate cyclic AMP (cAMP)-mediated intracellular response in renal cells by triggering the beta-3 subtype adrenergic receptor (BAR3).
The invention concerns a system based on a nano-transducer able to modify a target DNA sequence in a cell in order to delete harmful mutations underlying genetic diseases.
the new patented compounds are based on a potent reversible noncovalent mechanism of action, which is useful for treating MAGL-mediated diseases, such as neuroinflammation/degeneration, pain, multiple sclerosis/amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease.
The present invention relates to the development of novel isoindoline derivatives as activators of AMPK (Adenosine MonoPhosphate-activated protein Kinase), a key enzyme in cellular metabolism. The compounds, with original chemical structure, can be usefully employed for the prevention and treatment [...]
The present invention relates to the development of novel benzofuran derivatives able to activate AMPK (Adenosine MonoPhosphate-activated protein Kinase), a key enzyme in the regulation of immune homeostasis
